Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI

  1. Klimek, Ludger
  2. Bergmann, Karl-Christian
  3. Brehler, Randolf
  4. Pfützner, Wolfgang
  5. Zuberbier, Torsten
  6. Hartmann, Karin
  7. Jakob, Thilo
  8. Novak, Natalija
  9. Ring, Johannes
  10. Merk, Hans
  11. Hamelmann, Eckard
  12. Ankermann, Tobias
  13. Schmidt, Sebastian
  14. Untersmayr, Eva
  15. Hötzenecker, Wolfram
  16. Jensen-Jarolim, Erika
  17. Brockow, Knut
  18. Mahler, Vera
  19. Worm, Margitta

Download
Upload.pdf 725,80KB
WeightNameValue
1000 Titel
  • Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
1000 Autor/in
  1. Klimek, Ludger |
  2. Bergmann, Karl-Christian |
  3. Brehler, Randolf |
  4. Pfützner, Wolfgang |
  5. Zuberbier, Torsten |
  6. Hartmann, Karin |
  7. Jakob, Thilo |
  8. Novak, Natalija |
  9. Ring, Johannes |
  10. Merk, Hans |
  11. Hamelmann, Eckard |
  12. Ankermann, Tobias |
  13. Schmidt, Sebastian |
  14. Untersmayr, Eva |
  15. Hötzenecker, Wolfram |
  16. Jensen-Jarolim, Erika |
  17. Brockow, Knut |
  18. Mahler, Vera |
  19. Worm, Margitta |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-04-19
1000 Erschienen in
1000 Quellenangabe
  • 30:79-95
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40629-021-00165-7 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054127/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty. METHODS: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI). RESULTS: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts. CONCLUSION: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose.
1000 Sacherschließung
lokal Safety
gnd 1206347392 COVID-19
lokal Corona virus
lokal Allergic reaction
lokal Anaphylactic reaction
lokal Vaccination
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S2xpbWVrLCBMdWRnZXI=|https://frl.publisso.de/adhoc/uri/QmVyZ21hbm4sIEthcmwtQ2hyaXN0aWFu|https://frl.publisso.de/adhoc/uri/QnJlaGxlciwgUmFuZG9sZg==|https://frl.publisso.de/adhoc/uri/UGbDvHR6bmVyLCBXb2xmZ2FuZw==|https://frl.publisso.de/adhoc/uri/WnViZXJiaWVyLCBUb3JzdGVu|https://frl.publisso.de/adhoc/uri/SGFydG1hbm4sIEthcmlu|https://frl.publisso.de/adhoc/uri/SmFrb2IsIFRoaWxv|https://frl.publisso.de/adhoc/uri/Tm92YWssIE5hdGFsaWph|https://frl.publisso.de/adhoc/uri/UmluZywgSm9oYW5uZXM=|https://frl.publisso.de/adhoc/uri/TWVyaywgSGFucw==|https://frl.publisso.de/adhoc/uri/SGFtZWxtYW5uLCBFY2thcmQ=|https://frl.publisso.de/adhoc/uri/IEFua2VybWFubiwgVG9iaWFz|https://frl.publisso.de/adhoc/uri/U2NobWlkdCwgU2ViYXN0aWFu|https://frl.publisso.de/adhoc/uri/VW50ZXJzbWF5ciwgRXZh|https://frl.publisso.de/adhoc/uri/IEjDtnR6ZW5lY2tlciwgV29sZnJhbQ==|https://frl.publisso.de/adhoc/uri/SmVuc2VuLUphcm9saW0sIEVyaWth|https://frl.publisso.de/adhoc/uri/QnJvY2tvdywgS251dA==|https://d-nb.info/gnd/1115010409|https://frl.publisso.de/adhoc/uri/V29ybSwgTWFyZ2l0dGE=
1000 Label
1000 Förderer
  1. Projekt DEAL |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. Open Access funding
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Projekt DEAL |
    1000 Förderprogramm Open Access funding
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6431955.rdf
1000 Erstellt am 2022-03-03T14:45:33.641+0100
1000 Erstellt von 323
1000 beschreibt frl:6431955
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet 2022-03-16T07:51:08.205+0100
1000 Objekt bearb. Wed Mar 16 07:50:51 CET 2022
1000 Vgl. frl:6431955
1000 Oai Id
  1. oai:frl.publisso.de:frl:6431955 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source